X
xCures
Biotech & Life Sciences · San Francisco, United States · Founded 2018
AI-powered platform providing real-time healthcare data for treatment decision support and actionable insights MoreLess
xCures, founded in 2018, operates in the healthcare sector, focusing on leveraging artificial intelligence (AI) to improve patient outcomes. The company provides a platform that extracts, normalizes, and structures real-time healthcare data to support treatment decisions. This platform is particularly beneficial for oncologists and cancer patients, offering rapid and comprehensive access to critical data and actionable insights. xCures primarily serves healthcare providers, researchers, and pharmaceutical companies. The business model revolves around licensing its AI-powered platform to these clients, generating revenue through subscription fees and data analytics services. By addressing the complexities of large-scale cancer patient data and fragmented medical records, xCures aims to transform healthcare data into clinically actionable insights. The company also collaborates with other entities to enhance precision medicine guidelines and support investigational cancer treatments. Keywords: AI, healthcare, oncology, data analytics, real-time data, treatment support, precision medicine, cancer research, clinical insights, subscription model.
Company overview
xCures company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2018
- Headquarters
- San Francisco, United States
- Employees
- 58
- Open positions
- 2
- Dealroom signal
- 88.7
Valuation & funding
xCures funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Jun 2026 | $46M | $127M | Spring Mountain Capital · Innovius Capital | ↗ |
| CONVERTIBLEOther financing | Dec 2023 | $0 | — | HealthTech Capital | ↗ |
| SERIES AOther financing | Apr 2022 | — | — | Undisclosed | ↗ |
| SERIES AOther financing | Jun 2021 | $13M | $51M | Undisclosed | ↗ |
| FundingOther financing | Sep 2020 | $0 | — | Undisclosed | — |
| FundingOther financing | Jan 2020 | Vanedge Capital | — | ||
| FundingOther financing | Jun 2019 | Undisclosed | — | ||
| FundingOther financing | Feb 2018 | Lauder Partners | — |
Growth signals
xCures website traffic
Latest recorded traffic for xCures is 50K monthly website visits, up 117.4% over the last three months. xCures's team grew 31.8% over the past year.
Comparisons
xCures compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
xCures's talent
Source: Dealroom Talent Intelligence.
Investors
5 investors on xCures's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where xCures has talent and traffic
team presence
In the news
Latest news about xCures
Recent press, funding announcements, and product moves mentioning xCures — open to read from the original sources.
Market sentiment
What the market is saying about xCures
An AI-synthesized read of the highest-engagement posts about xCures on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See xCures’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.